Editorial
Understanding KRAS for better targeting
Translational Lung Cancer Research
2023;
12
(2)
:181-183
.
(28 February 2023)
Surgical series in mesothelioma: navigating between biases
Translational Lung Cancer Research
2023;
12
(2)
:184-186
.
(28 February 2023)
Some like it hot: the potential role of hyperthermic intrathoracic chemotherapy in the multimodality treatment of pleural mesothelioma
Translational Lung Cancer Research
2023;
12
(2)
:187-189
.
(28 February 2023)
Pleurectomy decortication is the preferred surgical procedure in pleural mesothelioma
Translational Lung Cancer Research
2023;
12
(2)
:190-192
.
(28 February 2023)
Do we still need to debate the merits of pleurectomy/decortication vs. extrapleural pneumonectomy for malignant pleural mesothelioma?
Translational Lung Cancer Research
2023;
12
(2)
:193-196
.
(28 February 2023)
Spare the lung: surgical treatment approach for malignant pleural mesothelioma
Translational Lung Cancer Research
2023;
12
(2)
:197-199
.
(28 February 2023)
Molecular minimal residual disease in resected non-small cell lung cancer (NSCLC): results of specifically designed interventional clinical trials eagerly awaited
Translational Lung Cancer Research
2023;
12
(2)
:200-203
.
(28 February 2023)
Adjuvant chemotherapy for locally advanced non-small cell lung cancer: still state of the art or an outdated therapy?
Translational Lung Cancer Research
2023;
12
(2)
:204-206
.
(28 February 2023)
Original Article
Supervision by an experienced surgeon can reduce the learning curve of uniportal thoracoscopic lobectomy
Translational Lung Cancer Research
2023;
12
(2)
:207-218
.
(28 February 2023)
Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
Translational Lung Cancer Research
2023;
12
(2)
:219-229
.
(28 February 2023)
A novel cuproptosis-related lncRNA signature to predict prognosis and immune landscape of lung adenocarcinoma
Translational Lung Cancer Research
2023;
12
(2)
:230-246
.
(28 February 2023)
Cost-effectiveness of diagnostic tests during follow-up in lung cancer patients: an evidence-based study
Translational Lung Cancer Research
2023;
12
(2)
:247-256
.
(28 February 2023)
Peripheral T-cell receptor repertoire dynamics in small cell lung cancer
Translational Lung Cancer Research
2023;
12
(2)
:257-265
.
(28 February 2023)
Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29)
Translational Lung Cancer Research
2023;
12
(2)
:266-276
.
(28 February 2023)
Integrated analysis reveals the microenvironment of non-small cell lung cancer and a macrophage-related prognostic model
Translational Lung Cancer Research
2023;
12
(2)
:277-294
.
(28 February 2023)
Integrative genomic profiling reveals characteristics of lymph node metastasis in small cell lung cancer
Translational Lung Cancer Research
2023;
12
(2)
:295-311
.
(28 February 2023)
Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer—a retrospective cohort study
Translational Lung Cancer Research
2023;
12
(2)
:312-321
.
(28 February 2023)
Review Article
Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer—current status and future directions
Translational Lung Cancer Research
2023;
12
(2)
:322-336
.
(28 February 2023)
Early-stage anaplastic lymphoma kinase (ALK)-positive lung cancer: a narrative review
Translational Lung Cancer Research
2023;
12
(2)
:337-345
.
(28 February 2023)
Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development—a narrative review
Translational Lung Cancer Research
2023;
12
(2)
:346-368
.
(28 February 2023)
Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer—a narrative review
Translational Lung Cancer Research
2023;
12
(2)
:369-378
.
(28 February 2023)
Targeting lung cancer brain metastases: a narrative review of emerging insights for anaplastic lymphoma kinase (ALK)-positive disease
Translational Lung Cancer Research
2023;
12
(2)
:379-392
.
(28 February 2023)
Erratum
Erratum to neoadjuvant chemo-immunotherapy for lung cancer: how much is too much?
Translational Lung Cancer Research
2023;
12
(2)
:393-394
.
(28 February 2023)
